Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial
Creators: name: Fowler, Robert A.
name: Mittmann, Nicole
name: Geerts, William H.
name: Heels-Ansdell, Diane
name: Gould, Michael K.
name: Guyatt, Gordon H.
name: Krahn, Murray
name: Finfer, Simon
name: Pinto, Ruxandra
name: Chan, Brian
name: Ormanidhi, Orges
name: Arabi, Yaseen
name: Qushmaq, Ismael
name: Rocha, Marcelo G.
name: Dodek, Peter M.
name: McIntyre, Lauralyn
name: Hall, Richard
name: Ferguson, Niall D.
name: Mehta, Sangeeta
name: Marshall, John C.
name: Doig, Christopher J.
name: Muscedere, John
name: Jacka, Michael J.
name: Klinger, James R.
name: Vlahakis, Nicholas
name: Orford, Neil
name: Seppelt, Ian
name: Skrobik, Yoanna K.
name: Sud, Sachin
name: Cade, John F.
name: Cooper, Jamie
name: Cook, Deborah
Publisher: name: BioMed Central
Year: 2016

description: Background: Venous thromboembolism (VTE) is a common complication of critical illness with important clinical consequences. The Prophylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) is a multicenter, blinded, randomized controlled trial comparing the effectiveness of the two most common pharmocoprevention strategies, unfractionated heparin (UFH) and low molecular weight heparin (LMWH) dalteparin, in medical-surgical patients in the intensive care unit (ICU). E-PROTECT is a prospective and concurrent economic evaluation of the PROTECT trial. Methods/Design: The primary objective of E-PROTECT is to identify and quantify the total (direct and indirect, variable and fixed) costs associated with the management of critically ill patients participating in the PROTECT trial, and, to combine costs and outcome results to determine the incremental cost-effectiveness of LMWH versus UFH, from the acute healthcare system perspective, over a data-rich time horizon of ICU admission and hospital admission. We derive baseline characteristics and probabilities of in-ICU and in-hospital events from all enrolled patients. Total costs are derived from centers, proportional to the numbers of patients enrolled in each country. Direct costs include medication, physician and other personnel costs, diagnostic radiology and laboratory testing, operative and non-operative procedures, costs associated with bleeding, transfusions and treatment-related complications. Indirect costs include ICU and hospital ward overhead costs. Outcomes are the ratio of incremental costs per incremental effects of LMWH versus UFH during hospitalization; incremental cost to prevent a thrombosis at any site (primary outcome); incremental cost to prevent a pulmonary embolism, deep vein thrombosis, major bleeding event or episode of heparin-induced thrombocytopenia (secondary outcomes) and incremental cost per life-year gained (tertiary outcome). Pre-specified subgroups and sensitivity analyses will be performed and confidence intervals for the estimates of incremental cost-effectiveness will be obtained using bootstrapping. Discussion: This economic evaluation employs a prospective costing methodology concurrent with a randomized controlled blinded clinical trial, with a pre-specified analytic plan, outcome measures, subgroup and sensitivity analyses. This economic evaluation has received only peer-reviewed funding and funders will not play a role in the generation, analysis or decision to submit the manuscripts for publication. Trial registration: Clinicaltrials.gov Identifier: NCT00182143 . Date of registration: 10 September 2005.